How Leqvio Lowers LDL Cholesterol
Leqvio (inclisiran) is an injectable small interfering RNA (siRNA) that targets PCSK9, a protein that regulates LDL cholesterol levels. It binds to PCSK9 messenger RNA in the liver, triggering its degradation via RNA interference (RNAi). This reduces PCSK9 production, allowing more LDL receptors on liver cells to recycle LDL cholesterol from the blood instead of letting it circulate.[1]
Administered as two subcutaneous doses six months apart, then every six months, it sustains LDL reductions of 40-52% in clinical trials, on top of statins.[2]
What Is PCSK9 and Why Target It?
PCSK9 binds to LDL receptors on hepatocytes, marking them for destruction. Fewer receptors mean less LDL clearance from blood. By silencing PCSK9 gene expression, Leqvio boosts receptor numbers and activity, directly pulling LDL particles into the liver for breakdown.[1][3]
How Does It Differ from Statins or Other LDL Drugs?
Statins block cholesterol synthesis in the liver, indirectly raising LDL receptors. Leqvio specifically knocks down PCSK9 via RNAi, offering additive effects—patients on statins see extra 50% LDL drops. Unlike monoclonal antibodies like Repatha (evolocumab), which also inhibit PCSK9 but require biweekly injections, Leqvio's twice-yearly dosing stems from its liver-specific delivery via GalNAc conjugation.[2][4]
| Drug | Mechanism | Dosing | LDL Reduction (with statins) |
|------|-----------|--------|------------------------------|
| Leqvio (inclisiran) | siRNA silencing PCSK9 mRNA | 2 doses/year | 40-52% |
| Repatha (evolocumab) | PCSK9 monoclonal antibody | Every 2 weeks | 50-60% |
| Statins (e.g., rosuvastatin) | HMG-CoA reductase inhibition | Daily | 30-50% |
Clinical Evidence on Effectiveness
In ORION trials (n=3,655), Leqvio cut LDL by 51% at 18 months versus placebo, reducing major cardiovascular events by 23-34% in high-risk groups. Effects peak at 30 days post-dose and last six months due to persistent mRNA silencing.[2][5]
Who Gets Leqvio and When?
FDA-approved for adults with primary hyperlipidemia or CVD needing extra LDL lowering despite maximum statin therapy. Not first-line; used when oral options fail. European approval similar via EMA.[3]
Common Side Effects and Risks
Injection-site reactions (8%), arthralgia (5%), and bronchitis (5%) most reported; rare serious issues like allergic reactions. Long-term data shows no liver toxicity or immunogenicity issues after 4 years.[2][5]
Cost and Access Details
List price ~$6,500 per dose (two doses/year), but patient assistance caps copays at $10/month for eligible. Patent protection extends to 2030 in the US.[6]
[1]: Leqvio Prescribing Information (Novartis)
[2]: NEJM: ORION-10/11 Trials
[3]: FDA Approval Summary
[4]: Repatha Prescribing Information (Amgen)
[5]: Lancet: ORION-4 Preview
[6]: DrugPatentWatch: Leqvio Patents